Showing 6711-6720 of 9119 results for "".
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- From SCALE 2026: Microneedling Treatment Reduces Periorbital Wrinkle Severityhttps://practicaldermatology.com/news/microneedling-treatment-reduces-periorbital-wrinkle-severity/2487121/A prospective clinical study presented at the 2026 Music City SCALE Annual Meeting demonstrated significant improvement in periorbital wrinkles following treatment with the SkinStylus SteriLock MicroSystem (Hydrafacial LLC). The study evaluated the safety and effic
- Long-Term Dupilumab Use Linked to Delayed Relapse in AD: Studyhttps://practicaldermatology.com/news/long-term-dupilumab-use-linked-to-delayed-relapse-in-ad-study/2487027/Patients with moderate-to-severe atopic dermatitis (AD) treated with dupilumab experienced durable symptom control and delayed relapse with long-term therapy, according to a real-world retrospective study published in the Journal
- Reduced AMP Expression Seen in Sensitive Skin Syndrome: Pilot Studyhttps://practicaldermatology.com/news/reduced-amp-expression-seen-in-sensitive-skin-syndrome-pilot-study/2486974/A pilot study published in the Journal of the American Academy of Dermatology evaluated whether key pathophysiologic features of rosacea—Demodex colonization and antimicrobial peptide (AMP) dysregulation—are also present in
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://practicaldermatology.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Analysis: PRS Improves Melanoma Risk Predictionhttps://practicaldermatology.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a
- Incyte Reports Positive Vitiligo Phase 3 Data Supporting JAK Therapieshttps://practicaldermatology.com/news/incyte-reports-positive-vitiligo-phase-3-data-supporting-jak-pipeline/2486888/Incyte provided updated data on two therapies in its dermatology pipeline during its recent earnings call, according to a statement from the company. Ruxolitinib Update
- AQUA Announces Partnership with Steele Dermatologyhttps://practicaldermatology.com/news/aqua-announces-partnership-with-steele-dermatology/2486768/AQUA Dermatology has announced a new partnership with Steele Dermatology, expanding its presence in the Atlanta metropolitan area, according to a press release.AQUA, backed by private equity firms Gryphon Investors and GTCR, continues to scale its network
- AI Dermatology Tools Improve Patient Diagnostic Accuracy in Survey Studyhttps://practicaldermatology.com/news/ai-dermatology-tools-improve-patient-diagnostic-accuracy-in-survey-study/2486637/An AI-powered dermatology application was associated with improved consumer understanding of skin conditions, according to new research published in JAMA Dermatology. The study includ